medigraphic.com
SPANISH

MediSan

ISSN 1029-3019 (Electronic)
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2018, Number 03

<< Back Next >>

MediSan 2018; 22 (03)

Cost-benefit of the treatment with Heberprot-P® in patients with diabetic foot

Mesa PEJ, Peregrino CG, Rosell VL, Fong SR
Full text How to cite this article

Language: Spanish
References: 0
Page: 223-233
PDF size: 682.82 Kb.


Key words:

cost-benefit, diabetes mellitus, diabetic foot, Heberprot-P®, primary health care.

ABSTRACT

A descriptive and cross-sectional study of 56 patients with diabetes mellitus to whom diabetic foot was diagnosed, belonging to the health area of "Josué País García" University Polyclinic in Santiago de Cuba was carried out from January to December, 2016, in order to determine the cost-benefit of the treatment with Heberprot-P®. This treatment was beneficial, because the cure of all patients was achieved. It is concluded that, in spite of the high cost that represents the administration of the novel treatment, it constituted a significant benefit for those affected, since the use of expensive surgical techniques and the amputations were avoided; also, it favored a better life quality, the socially useful life was expanded, the problems decreased from the social point of view as well as the high expenditure of expenses in social care.





2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

MediSan. 2018;22